Which patients with B-cell acute lymphoblastic leukaemia are eligible for Kymriah (tisagenlecleucel)?

Kymriah (tisagenlecleucel) is indicated for paediatric and young adult patients up to and including 25 years old with B-cell acute lymphoblastic leukaemia that is refractory, in relapse post-transplant, or in second or later relapse.